Market Research Logo

Growth Factor Inhibitors: Markets and Opportunities for a Growing Pipeline

Growth factors are gene products that play important roles in the regulation of cell division and tissue proliferation. Generally, the binding of a growth factor to its receptor initiates or blocks the ability of cells to divide and multiply. Blood and tissue growth factors have become exciting targets for compounds intended to inhibit or slow the mechanisms involved in their function or growth.

This report highlights the research into, and the current and potential key world markets for, products that inhibit the functioning of growth factors and the development of angiogenesis. These inhibitors include proteins, antibodies, and a variety of compounds currently targeted at four key diseases:

  • Cancer;
  • Age-Related Macular Degeneration;
  • Rheumatoid Arthritis;
  • Psoriasis.

The world market for inhibitors of growth factors and angiogenesis will more than triple between 2003 and 2007. Most of the growth will occur in the rheumatology market, where growth factor inhibitors, such as Enbrel and Remicade, have already established themselves. The cancer market will evolve as a large segment as well, as the use of Iressa and Herceptin gains acceptance and additional indications.

This report focuses on the current and future markets for drugs used to inhibit the growth of tumors, cancerous lesions, and which can be used to fight other diseases that involve the unwanted or abnormal growth of blood vessels, such as age-related macular degeneration and rheumatoid arthritis. The report generally reviews the nature and direction of research, as well as the markets for currently available growth factor inhibitor drugs.

Market forecasts are based on an examination of current market conditions and on investigations into the development of new products by key companies. This information is also weighted with the projected timing and the probability of receiving FDA and other regulatory approval to market products. Interviews and correspondence with company executives, clinicians, researchers, and public health officials form the basis of the conclusions. Market data were developed using a combination of these interviews, market modeling involving epidemiology and likely drug approvals, and information gathered from company product literature, other corporate brochures and documents, government databases, and the scientific and trade press.

Chapter One: Executive Summary

  • Blood and Tissue Growth Factors
    • Colony-Stimulating Growth Factors
    • Interleukins
    • Vascular Endothelial Growth Factor (VEGF)
    • Fibroblast Growth Factors (FGFs)

  • Angiogenesis
  • Angiogenesis Inhibition
  • Indications for Growth Factor Inhibition
    • Cancer
    • Ophthalmology
    • Rheumatology
    • Dermatology

  • Market Drivers
  • Worldwide Market Forecast Synopsis
  • Scope and Methodology

Chapter Two: Introduction

  • Growth Factors Defined
  • Growth Factor Receptors
  • Angiogenesis Defined
  • Growth Factors Related to Angiogenesis
    • Epidermal Growth Factor (EGF)
    • Vascular Endothelial Growth Factor (VEGF)
    • Tumor Necrosis Factors (TNFs)

  • Growth Factor and Angiogenesis Inhibitors
    • Cytokine/TNF Targets
    • EGF/VEGF Targets
    • MMP Inhibitors

  • Receptor Targeting Agents
  • Tumor Growth
  • Vascularization
  • Applications for Growth Factor- and Angiogenesis Inhibitors
    • Cancer
    • Low Toxicity
    • Drug Resistance

  • Ophthalmology
    • Age Related Macular Degeneration

  • Rheumatology
    • Rheumatoid Arthritis
    • Psoriatic Arthritis
    • Osteoarthritis

  • Dermatology
  • Demand Analysis
    • Cancer
    • Age Related Macular Degeneration
    • Rheumatoid Arthritis
    • Dermatology

  • Challenges Facing Developers
    • Biologics Issues
    • The Biologics Challenge
    • Licensing Mechanism
    • Method of Delivery

Chapter Three: Research Trends

  • An Emerging Science and Its Markets
    • In the Pipeline
    • Drug Candidates in Clinical Trials

  • Special Needs
  • Specific Research Highlights
    • Tetrathiomolybdate
    • RhuMab VEGF
    • Parathyroid Hormone-Related Peptide
    • Endostatin/Tumstatin
    • Radiation/Endostatin
    • Thrombospondin-1
    • Inhibiting Proteins
    • Regulating Cellular Processes
    • Circumin
    • Drug Resistance

Chapter Four: The Market for Growth Factor Inhibitors

  • Overall Forecasts
  • Cancer
  • Ophthalmology
  • Rheumatology
  • Dermatology
  • Geographic Markets
  • Products on the Market
    • Herceptin
    • Iressa
    • Enbrel
    • Remicade
    • Humira
    • Kineret

  • Major Market Players and Product Share
  • Growth Factor Products for the Research Market

Chapter Five: Company Profiles

  • Abbott Laboratories
  • Abgenix Inc.
  • AbTech
  • Aeterna Laboratories Inc.
  • Amgen Inc.
  • Angiogene Pharmaceuticals Ltd.
  • Aphton Corp.
  • AstraZeneca PLC
  • Aventis SA
  • BioStratum Inc.
  • Boston Life Sciences Inc.
  • Bristol-Myers Squibb Co.
  • Celgene Corp.
  • Cephalon Inc.
  • CollaGenex Pharmaceuticals Inc.
  • Curis Inc.
  • EntreMed Inc.
  • Eyetech Pharmaceuticals Inc.
  • Genentech Inc.
  • Genaera Corp.
  • GenVec Inc.
  • Human Genome Sciences Inc.
  • Ilex Oncology Inc.
  • ImClone Systems Inc.
  • Insmed Inc.
  • Isis Pharmaceuticals Inc.
  • Johnson & Johnson
  • MedImmune Inc.
  • Novartis International AG
  • OSI Pharmaceuticals Inc.
  • Pfizer Inc.
  • Progen Industries Ltd.
  • Regeneron Pharmaceuticals Inc.
  • (F. Hoffmann-La) Roche Ltd.
  • Sangamo BioSciences Inc.
  • SuperGen
  • Supratek Pharma Inc.
  • Wyeth

List of Exhibits
Chapter One: Executive Summary

  • Table 1-1: World Market for Growth Factor Inhibitors by Therapeutic Segment 2003-2007

Chapter Two: Introduction

  • Table 2-1: Estimated Cancer Prevalence in the Seven Major World Healthcare Markets 2000-2006
  • Table 2-2: U.S. Prevalence of Rheumatoid Arthritis and Severe Rheumatoid Arthritis 2003-2007
  • Table 2-3: U.S. Prevalence of Psoriasis and Psoriatic Arthritis 2003-2007

Chapter Three: Research Trends

  • Table 3-1: Selected Growth Factor-Based Therapies in Development
  • Table 3-2: Anti-Angiogensis Candidates in Current Clinical Trials in the United States by Mechanism of Action
  • Table 3-3: Antiangiogenic Medicines in Recent European Clinical Trials<

Chapter Four: The Market for Growth Factor Inhibitors

  • Table 4-1: World Market for Growth Factor Inhibitor Therapeutics 2003-2007
  • Table 4-2: Cancer Market for Growth Factor Inhibitor Therapeutics 2003-2007
  • Table 4-3: Age-Related Macular Degeneration Market for Growth Factor Inhibitor Therapeutics 2003-2007
  • Table 4-4: Rheumatology Market for Growth Factor Inhibitor Therapeutics 2003-2007
  • Table 4-5: Dermatology Market for Growth Factor Inhibitor Therapeutics 2003-2007
  • Figure 4-1: Estimated Distribution of Growth Factor Inhibitor and Anti-Angiogenesis Revenues by Region 2003
  • Table 4-6: Cancer Market for Growth Factor Inhibitors by Geographical Region 2003-2007
  • Table 4-7: Ophthalmologic Market for Growth Factor Inhibitors by Geographical Region 2003-2007
  • Table 4-8: Rheumatology Market for Growth Factor Inhibitors by Geographical Region 2003-2007
  • Table 4-9: Dermatology Market for Growth Factor Inhibitors by Geographical Region
  • Table 4-10: Market Share for Leading Growth Factor Therapeutics in the Cancer Segment 2003
  • Table 4-11: Market Share for Leading Growth Factor Therapeutics Rheumatology Segment 2003

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report